Article -> Article Details

Cardiac biomarkers are often referred to as cardiac markers. The cardiac biomarkers (endogens, including enzymes, hormones, and proteins) are released into the blood if the heart is damaged or stressed. Generally, they are used to treat heart attack and acute coronary syndrome (ACS) or disorders associated with insufficient blood flow to the core

According to Market Research Future (MRFR), Cardiac Biomarkers Market is expected to cross USD 4236.02 Million 2025 at a CAGR of 16.36% by 2025 (forecast period). The research report serves as insight and knowledge repository for all market aspects including, regional markets, technology, types, and applications.

There are a number of factors that impact the growth of the cardiac biomarkers market. Some of the key factors include a rise in demand for diagnostic and testing of various cardiovascular diseases, development and advancement in cardiac biomarkers, and growth in the patient population suffering from cardiovascular diseases.

Other key growth drivers include the rise in the number of new cardiovascular cases diagnosed each year and the increase in demand for disease-specific treatment in which cardiac biomarkers are used. The increasing prevalence of cardiovascular diseases is expected to boost the cardiac biomarkers market during the forecast period.

Market Dynamics

There are a variety of factors that affect the development of the demand for cardiac biomarkers. Some of the main factors include growing demand for the diagnosis and testing of various cardiovascular diseases, the production and advancement of cardiac biomarkers and the growth of the patient population suffering from cardiovascular disease. Other primary growth factors include a rise in the number of new cardiovascular cases diagnosed per year and an increase in demand for disease-specific care in which cardiac biomarkers are used. Increased prevalence of the cardiovascular disease is projected to fuel the demand for cardiac biomarkers during the forecast period. Approximately 17.7 million people die each year from cardiovascular diseases (CVDs), according to the World Health Organization, and it is estimated to be the cause of 31% of the total deaths worldwide. About 80% of all deaths from CVDs are attributed to heart attacks and strokes. Nonetheless, the demand for cardiac biomarkers is experiencing constraints due to the emergence of other methods for cardiovascular disease diagnosis, along with high procedural costs, lack of full proof assurance, and strong competition among existing players.

Segmentation 

Based on type, the cardiac biomarkers market can be segmented into Myocardial muscle Creatine Kinase (CK-MB), troponins (T and I), myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, ischemia-modified albumin (IMA), and others. Owing to its prodigious sensitivity and ability to reliably diagnose the heart events of an acute coronary syndrome (ACS), Troponins I and T are the leading revenue-generating segment in the global cardiac biomarkers market.

The location of testing is further segmented into point of care testing and laboratory testing. The point of care testing is projected to see steady growth in the forecast period due to its increasing popularity. The laboratory testing segment dominated the global market for cardiac biomarkers. Increased demand for cardiovascular disease diagnostics is increasing the revenue of this segment.

Key Players 

Key companies operating in the global cardiac biomarkers market are Abbott Laboratories, ACS Biomarker (The Netherlands), BD (Becton, Dickinson, and Company) (US), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), Hoffmann-La Roche Ltd (Switzerland), Johnson and Johnson (US), Quidel Corporation (US), Randox Laboratories Limited (UK), Siemens AG (Germany), Thermo Fisher Scientific, Inc. (the US), Trivitron Healthcare Pvt. Ltd. (India), and Novartis (Switzerland)